Early Morning Functioning in Stimulant-Treated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, and its Impact on Caregivers
- PMID: 26151738
- PMCID: PMC4576958
- DOI: 10.1089/cap.2014.0160
Early Morning Functioning in Stimulant-Treated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, and its Impact on Caregivers
Abstract
Objective: The purpose of this study was to examine the temporal occurrence and severity of inadequate attention-deficit/hyperactivity disorder (ADHD) symptom control throughout the day, and, more specifically, the frequency and severity of associated functional impairments and their apparent emotional impact on parents and caregivers during the early morning routine before school, in children and adolescents with ADHD currently treated with stable doses of stimulant medications.
Methods: Information was obtained from 201 primary caregivers of children and adolescents with ADHD using a self-administered, on-line quantitative research survey.
Results: Inadequately controlled ADHD symptoms were rated as most severe during the evening homework time and the early morning routine. The majority of caregivers reported early morning ADHD symptoms and impairment of early morning functioning (EMF) as moderate to severe. Caregiver reactions to their child's early morning ADHD symptoms and unwanted behaviors included feeling overwhelmed, exhausted, and constantly stressed.
Conclusions: Control of EMF impairments from inadequately controlled ADHD symptoms is a significant unmet need in children and adolescents with ADHD treated with stable morning doses of stimulant medications. Current orally administered stimulant treatment options have not addressed this challenge.
Figures





Similar articles
-
Early Morning Functional Impairments in Stimulant-Treated Children with Attention-Deficit/Hyperactivity Disorder Versus Controls: Impact on the Family.J Child Adolesc Psychopharmacol. 2017 Oct;27(8):715-722. doi: 10.1089/cap.2016.0164. Epub 2017 Apr 10. J Child Adolesc Psychopharmacol. 2017. PMID: 28394175 Free PMC article.
-
Caregiver Treatment Preferences for Children with a New Versus Existing Attention-Deficit/Hyperactivity Disorder Diagnosis.J Child Adolesc Psychopharmacol. 2017 Apr;27(3):234-242. doi: 10.1089/cap.2016.0157. Epub 2016 Dec 19. J Child Adolesc Psychopharmacol. 2017. PMID: 27991834 Free PMC article.
-
Early Morning ADHD Symptoms and Functional Impairment: Impact on Patients and Caregivers, and Pharmacological Approaches to Management.CNS Drugs. 2023 Jan;37(1):31-44. doi: 10.1007/s40263-022-00978-2. Epub 2022 Dec 15. CNS Drugs. 2023. PMID: 36520318 Review.
-
Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.Pediatrics. 2004 Nov;114(5):e541-7. doi: 10.1542/peds.2004-0844. Pediatrics. 2004. PMID: 15520087
-
Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.Pediatrics. 2005 Jun;115(6):e749-57. doi: 10.1542/peds.2004-2560. Pediatrics. 2005. PMID: 15930203 Review.
Cited by
-
Risk factors for the difficulties in general activities across the day in Chinese children and adolescents with attention-deficit/hyperactivity disorder.Neuropsychiatr Dis Treat. 2018 Dec 31;15:157-166. doi: 10.2147/NDT.S187882. eCollection 2019. Neuropsychiatr Dis Treat. 2018. PMID: 30643414 Free PMC article.
-
Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.J Child Adolesc Psychopharmacol. 2019 Apr;29(3):181-191. doi: 10.1089/cap.2018.0122. Epub 2019 Feb 27. J Child Adolesc Psychopharmacol. 2019. PMID: 30810347 Free PMC article. Clinical Trial.
-
Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2-8. doi: 10.1089/cap.2018.0078. Epub 2018 Dec 21. J Child Adolesc Psychopharmacol. 2019. PMID: 30575407 Free PMC article. Clinical Trial.
-
A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.J Child Adolesc Psychopharmacol. 2020 Feb;30(1):2-14. doi: 10.1089/cap.2019.0070. Epub 2019 Aug 29. J Child Adolesc Psychopharmacol. 2020. PMID: 31464511 Free PMC article. Clinical Trial.
-
Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol. 2022 Jun;32(5):288-295. doi: 10.1089/cap.2022.0015. Epub 2022 Jun 3. J Child Adolesc Psychopharmacol. 2022. PMID: 35666231 Free PMC article.
References
-
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013
-
- Antrop I, Roeyers H, De Baecke L: Effects of time of day on classroom behaviour in children with ADHD. Sch Psychol Int 26:29–43, 2005
-
- Chang LR, Chiu YN, Wu YY, Gau SS: Father's parenting and father-child relationship among children and adolescents with attention-deficit/hyperactivity disorder. Compr Psychiatry 54:128–140, 2013 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical